| Literature DB >> 33915852 |
Vianney Gilard1,2, Abdellah Tebani2,3, Ivana Dabaj3,4, Annie Laquerrière2,5, Maxime Fontanilles6, Stéphane Derrey1, Stéphane Marret3,4, Soumeya Bekri2,3.
Abstract
Glioblastoma is the most common malignant brain tumor in adults. The current management relies on surgical resection and adjuvant radiotherapy and chemotherapy. Despite advances in our understanding of glioblastoma onset, we are still faced with an increased incidence, an altered quality of life and a poor prognosis, its relapse and a median overall survival of 15 months. For the past few years, the understanding of glioblastoma physiopathology has experienced an exponential acceleration and yielded significant insights and new treatments perspectives. In this review, through an original R-based literature analysis, we summarize the clinical presentation, current standards of care and outcomes in patients diagnosed with glioblastoma. We also present the recent advances and perspectives regarding pathophysiological bases as well as new therapeutic approaches such as cancer vaccination and personalized treatments.Entities:
Keywords: glioblastoma; molecular pathology; omics; pathogenesis; personalized therapies
Year: 2021 PMID: 33915852 DOI: 10.3390/jpm11040258
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426